Study of TTX-MC138 in Subjects With Advanced Solid Tumors
← catalyst calendarSponsored by TransCode Therapeutics (industry) · RNAZ — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
16actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-05 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Intervention
- Drug: TTX-MC138
Primary outcomes
what the primary-completion date above is the date OFDose Escalation - Adverse Events
measured Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year
Dose Escalation - Overall Response Rate (ORR)
measured Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year
Permalink · RNAZ's whole pipeline · Catalyst calendar · Every registered study · What changed